PureTech, Novartis create resTORbio | Chemical & Engineering News
Volume 95 Issue 14 | p. 19 | Concentrates
Issue Date: April 3, 2017

PureTech, Novartis create resTORbio

Department: Business
Keywords: start-ups, drug development, rapamycin, geriatrics

PureTech Health, an R&D and venture investment firm, has licensed two clinical-stage drug programs from Novartis and will create a subsidiary called resTORbio to further develop them. PureTech is putting about $15 million toward the effort in exchange for a 58% ownership stake. Novartis will also get an interest in resTORbio and be eligible for milestone payments and royalties. The drug candidates target inhibition of the mechanistic target of rapamycin complex 1 pathway in age-related immune conditions.

Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment